Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Modeling Heartland virus disease in mice and therapeutic intervention with 4'-fluorouridine.

Autor: Westover JB; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.; Institute for Antiviral Research, Utah State University, Logan, Utah, USA., Jung KH; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.; Institute for Antiviral Research, Utah State University, Logan, Utah, USA., Alkan C; Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA., Boardman KM; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.; Institute for Antiviral Research, Utah State University, Logan, Utah, USA., Van Wettere AJ; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.; Utah Veterinary Diagnostic Laboratory, Logan, Utah, USA., Martens C; Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Rojas I; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.; Institute for Antiviral Research, Utah State University, Logan, Utah, USA., Hicks P; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Thomas AJ; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.; Center for Integrated BioSystems, Utah State University, Logan, Utah, USA., Saindane MT; Emory Institute for Drug Development, Emory University, Atlanta, Georgia, USA., Bluemling GR; Emory Institute for Drug Development, Emory University, Atlanta, Georgia, USA., Mao S; Emory Institute for Drug Development, Emory University, Atlanta, Georgia, USA., Kolykhalov AA; Emory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.; Drug Innovation Ventures at Emory (DRIVE), Atlanta, Georgia, USA., Natchus MG; Emory Institute for Drug Development, Emory University, Atlanta, Georgia, USA., Bates P; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Painter GR; Emory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.; Drug Innovation Ventures at Emory (DRIVE), Atlanta, Georgia, USA.; Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USA., Ikegami T; Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA.; The Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch, Galveston, Texas, USA.; The Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston, Texas, USA., Gowen BB; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, USA.; Institute for Antiviral Research, Utah State University, Logan, Utah, USA.

Publikováno v: Journal of virology [J Virol] 2024 Apr 16; Vol. 98 (4), pp. e0013224. Date of Electronic Publication: 2024 Mar 21.

SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.

Autor: Lieber CM; Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA., Cox RM; Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA., Sourimant J; Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA., Wolf JD; Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA., Juergens K; Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, 98185, USA., Phung Q; Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, 98185, USA., Saindane MT; Emory Institute for Drug Development, Emory University, Atlanta, GA, 30329, USA., Smith MK; Emory Institute for Drug Development, Emory University, Atlanta, GA, 30329, USA., Sticher ZM; Emory Institute for Drug Development, Emory University, Atlanta, GA, 30329, USA., Kalykhalov AA; Emory Institute for Drug Development, Emory University, Atlanta, GA, 30329, USA., Natchus MG; Emory Institute for Drug Development, Emory University, Atlanta, GA, 30329, USA., Painter GR; Emory Institute for Drug Development, Emory University, Atlanta, GA, 30329, USA., Sakamoto K; Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA., Greninger AL; Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, 98185, USA., Plemper RK; Center for Translational Antiviral Research, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA. rplemper@gsu.edu.

Publikováno v: Nature communications [Nat Commun] 2022 Jul 29; Vol. 13 (1), pp. 4416. Date of Electronic Publication: 2022 Jul 29.